Angiogenesis in endocrine-related cancers

Endocrine-Related Cancer

Volumn 4, Issue 4, 1997, Pages 423-445

  Gasparini, G ^a  

^a BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BREAST CANCER; BREAST CARCINOGENESIS; CELL PROLIFERATION; ENDOMETRIUM CANCER; HUMAN; REVIEW;

EID: 0030733539     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0040423     Document Type: Review

References (130)

1. Abu-Jawdeh GM, Faix JD, Niloff J, Tognazzi K, Manseau E, Dvorak HF & Brown LF 1996 Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Laboratory Investigation 74 1105-1115.
2. Abulafia O, Triest WE, Sherer DM, Hansen CC & Ghezzi F 1995 Angiogenesis in endometrial hyperplasia and stage I endometrial carcinoma. Obstetrics and Gynecology 86 479-485.
3. Aranda FI & Laforga JB 1996 Microvessel quantitation in breast ductal invasive carcinoma. Pathology Research Practice 192 124-129.
4. Arnoletti JP, Albo D, Granick MS, Solomon MP, Castiglioni A, Rothman VL & Tuzynski GP 1995 Thrombospondin and transforming growth-factor-β1 increase expression of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in human MDA-MB-231 breast cancer cells. Cancer 76 998-1005.
5. Axelsson K, Ljung B-ME, More DH II, Thor AD, Chew KL, Edgerton SM, Smith HS & Mayall BH 1995 Tumor angiogenesis as a prognostic assay for invasive ductal breast carcinoma. Journal of the National Cancer Institute 87 997-1008.
6. Barth PJ, Weingartner K, Kohler HH & Bittinger A 1996 Assessment of the vascularization in prostatic carcinomas: A morphometric investigation. Human Pathology 27 1306-1310.
7. Bertin N, Clezardin P, Kubiak R & Frappart L 1997 Thrombospondin-1 and -2 messenger RNA expression in normal, benign, and neoplastic human breast tissues: Correlation with prognostic factors, tumor angiogenesis, and fibroblastic dermoplasia. Cancer Research 57 396-399.
8. Boocock CA, Charnock- Jones DS, Sharkey AM, McLaren J, Barker PJ, Wright KA, Twentyman PR & Smith SK 1995 Expression of vascular endothelial growth factor and its receptors fit and KDR in ovarian carcinoma. Journal of the National Cancer Institute 87 506-516.
9. Bostwick DG, Wheeler TM, Blute M, Barrett DM, MacLennan GT, Sebo TJ, Scardino FT, Humphrey PA, Hudson MA, Fradet Y, Miller GJ, Crawford ED, Blumenstein BA, Mahran HE & Miles BJ 1996. Optimized microvessel density analysis in prediction of cancer stage from prostate needle biopsies. Urology 48 47-57.
10. Bouck N 1996 p53 and angiogenesis. Biochimica et Biophysica Acta 1287 63-66.
11. Bouck N, Stellmach V & Hsu SC 1996 How tumors become angiogenic. In Advances in Cancer Research, vol 69, pp 135-174. Eds GF Vande Woude & G Klein. San Diego, CA: Academic Press.
12. Brawer MK, Deering RE, Brown M, Preston SD & Bigler SA 1994 Predictors of pathologic stage in prostatic carcinoma. Cancer 73 678-687.
13. Bremer GL, Tiebosch ATMG, van der Putten HWHM, Schouten HJA, de Haan J & Arends J-W 1996 Tumor angiogenesis: an independent prognostic parameter in cervical cancer. American Journal of Obstetrics and Gynecology 174 126-131.
14. 3 for angiogenesis. Science 264 569-571.
15. 3 blocks human breast cancer growth and angiogenesis in human skin. Journal of Clinical Investigation 96 1815-1822.
16. Cheresh DA 1996 Cell adhesion and angiogenesis. Trends in Cell Biology 6 462-468.
17. Coltrini D, Gualandris A, Nelli EE, Parolini S, Molinari-Tosatti MP, Quarto N, Ziehe M, Giavazzi R & Presta M 1995 Growth advantage and vascularization induced by basic fibroblast growth factor overexpression in endometrial HEC-I-B-cells: An export-dependent mechanism of action. Cancer Research 55 4729-4738.
18. Contrino J, Hair G, Kreutzer DL & Rickles FR 1996 In situ detection of tissue factor in vascular endothelial cells: Correlation with the malignant phenotype of human breast disease. Nature Medicine 2 209-215.
19. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR & Melaned MR 1990 Expression of the multidrug resistance gene product (P-Glycoprotein) in human normal and tumor tissues. Journal of Histochemistry and Cytochemistry 38 1277-1287.
20. Costa M, Danesi R, Agen C, Di Paolo A, Basolo F, Del Bianchi S & DelTacca M 1994 MCF-10A cells infected with the int-2 oncogene induce angiogenesis in the chick chorioallantoic membrane and in the rat mesentary. Cancer Research 54 9-11.
21. Costello P, McCann A, Carney DN & Dervan PA 1995 Prognostic significance of microvessel density in lymph node negative breast carcinoma. Human Pathology 26 1181-1184.
22. Dameron KM, Volpert OV, Tainsky MA & Bouck N 1994 Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science265 1582-1585.
23. Deng G, Lu Y, Ziotnikov G, Thor AD & Smith HS 1996 Loss of heterozygosity in normal tissue adjacent to breast carcinomas. Science 274 2057-2059.
24. van Diest PJ, Zevering JP, Zevering LC & Baak JPA 1995 Prognostic value of microvessel quantitation in cisplatin treated figo 3 and 4 ovarian cancer patients. Pathology Research Practice 191 25-30.
25. Dvorak HF 1986 Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. New England Journal of Medicine 315 1650-1659.
26. Ellis LM & Fidler IJ 1996 Angiogenesis and metastasis. European Journal of Cancer 32A 2451-2460
27. Esteller M, Garcia A, Martinez JM, Palones I, Cabero A & Reventos J 1995 Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction. Cancer 75 2139-2146.
28. Folkman J 1994 Angiogenesis and breast cancer. Journal of Clinical Oncology 12 441-443.
29. Folkman J 1995a Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Medicine 1 27-31.
30. Folkman J 1995b The influence of angiogenesis research on management of patients with breast cancer. Breast Cancer Research and Treatment 36 109-118.
31. Folkman J 1996 Angiogenesis and metastatic growth. Advances in Oncology 12 2-7.
32. Folkman J, Watson K, Ingber D & Hanahan D 1989 Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339 58-61.
33. Fox SB, Leek RD, Smith K, Hollyer J, Greenall M & Harris AL 1994 Tumor angiogenesis in node-negative breast carcinomas - relationship with epidermal growth factor receptor, estrogen receptor, and survival. Breast Cancer Research and Treatment 29 109-116.
34. Fox SB, Leek RD, Weekes MP, Whitehouse RM, Gatter KC & Harris AL 1995 Quantitation and prognostic value of breast cancer angiogenesis: Comparison of microvessel density, Chalkley count and computer image analysis. Journal of Pathology 177 275-283.
35. Fox SB, Westwood M, Moghaddam A, Comley M, Turley H, Whitehouse RM, Bicknell R, Gatter KC & Harris AL 1996 The angiogenic factor platelet-derived endothelial cell growth factor/thymidine phosphorylase is up-regulated in breast cancer epithelium and endothelium. British Journal of Cancer 73 275-280.
36. Fregene TA, Khanuja PS, Noto AC, Gehani SK, Van Egmont EM, Luz DA & Pienta KJ 1993 Tumor-associated angiogenesis in prostate cancer. Anticancer Research 13 2377-2381.
37. v integrins. Science 270 1500-1502.
38. 6 integrin in human breast carcinoma is correlated with reduced survival. Cancer Research 55 901-906.
39. Gasparini G 1996a Angiogenesis research up to 1996: A commentary on the state of art and suggestions for future studies. European Journal of Cancer 32A 2379-2385.
40. Gasparini G 1996b Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. European Journal of Cancer 32A 2485-2493.
41. Gasparini G & Harris AL 1997 p53 and angiogenesis in neoplasia. In ESO Scientific Updates, vol. 1, Prognostic and Predictive Value of p 53, pp 115-130. Ed JGM Klijn. Amsterdam: Elsevier Science.
42. Gasparini G, Weidner N, Bevilacqua P, Dalla Palma P, Caffo O, Barbareschi M, Boracchi P, Marubini E & Pozza F 1994 Tumor microvessel density, p53 expression, tumor size and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. Journal of Clinical Oncology 12 454-466.
43. Gasparini G, Barbareschi M, Boracchi P, Bevilacqua P, Verderio P, Dalla Palma P & Menard S 1995a 67-KDa laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. International Journal of Cancer 60 604-610.
44. Gasparini G, Barbareschi M, Boracchi P, Verderio P, Caffo O, Meli S, Dalla Palma P, Marubini E & Bevilacqua P 1995b Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy. Cancer Journal from Scientific American 1 131-141.
45. Gasparini G, Fox SB, Verderio P, Bonoldi E, Bevilacqua P, Boracchi P, Dante S, Marubini E & Harris AL 1996a Determination of angiogenesis adds information to estrogen receptor status in predicting the efficacy of adjuvant tamoxifen in node-positive breast cancer patients. Clinical Cancer Research 2 1191-1198.
46. Gasparini G, Bonoldi E, Viale G, Verderio P, Boracchi P, Panizzoni GA, Radaelli V, Di Bacco A, Guglielmi RB & Bevilacqua P 1996b Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. International Journal of Cancer (Predictive Oncology) 69 205-211.
47. Gasparini G, Toi M, Gion M, Verderio P, Dittadi R, Hanatani M, Matsubara I, Vinante O, Bonoldi E, Boracchi P, Gatti C, Suzuki I & Tominaga T 1997 Prognostic significance of vascular endothelial growth factor protein in node-negative breast carcinoma. Journal of the National Cancer Institute 89 139-147.
48. Gately S, Twardowski P, Stack MS, Patrick M, Boggio L, Cundiff DL, Schnaper HW, Madison L, Volpert O, Bouck N, Englild J, Kwaan HC & Soff GA 1996 Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin. Cancer Research 56 4887-4890.
49. Goulding H, Nik Abdul Rashid NF, Robertson F, Bell JA, Elston CW, Blamey RW & Ellis IO 1995 Assessment of angiogenesis in breast carcinoma: An important factor in prognosis? Human Pathology 26 1196-1200.
50. Guidi AJ, Abu-Jawdeh G, Berse B, Jackman RW, Tognazzi K, Dvorak HF & Brown LF 1995 Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in cervical neoplasia. Journal of the National Cancer Institute 87 1237-1245.
51. Guidi AJ, Abu-Jawdeh G, Tognazzi K, Dvorak HF & Brown LF 1996 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78 454-460.
52. Hanahan D & Folkman J 1996 Patterns of emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86 353-364.
53. Harper ME, Glynne-Jones E, Goddard L, Thurston VJ & Griffiths K 1996 Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. British Journal of Cancer 74 910-916.
54. Hollingsworth HC, Kohn EC, Steinberg SM, Rothenberg ML & Merino MJ 1995 Tumor angiogenesis in advanced stage ovarian carcinoma. American Journal of Pathology 147 33-41.
55. Horak ER, Leek R, Klenk N, LeJeune S, Smith K, Stuart N, Greenall M, Stepniewska K & Harris AL 1992 Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 340 1120-1124.
56. Howlett AR & Bissell M 1993 The influence of tissue microenviroment (stroma and extracellular matrix) on the development and function of mammary epithelium. Epithelial Cell Biology 2 79-89.
57. Howlett AR, Bailey N, Damsky C, Petersen OW & Bissell MJ 1995 Cellular growth and survival are mediated by β1 integrins in normal human breast epithelium but not in breast carcinoma. Journal of Cellular Science 108 1945-1957.
58. Huang A, Jin H & Wright JA 1995 Drug resistance and gene amplification potential regulated by transforming growth factor 1 gene expression. Cancer Research 55 1758-1762.
59. Hyder SM, Stancel GM, Chiappetta C, Murthy L, Boettger-Tong HL & Makela S 1996 Uterine expression of vascular endothelial growth factor is increased by estradiol and tamoxifen. Cancer Research 56 3954-3960.
60. Hynes RO 1992 Integrins: versatility, modulation and signaling in cell adhesion. Cell 69 11-25.
61. Incardona F, Leivalle JM, Morandi V, Lambert S, Legrand Y, Foidart JM & Legrand C 1995 Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Research 55 166-173.
62. Iruela-Arispe ML, Porter P, Bornstein P & Sage EH 1996 Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium. Journal of Clinical Investigation 97 403-412.
63. Ishihara A, Yoshida T, Tamaki H & Sakakura T 1995 Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance. Clinical Cancer Research 1 1035-1041.
64. Kainz C, Speiser P, Wanner C, Obermair A, Tempfer C, Sliutz G, Reinthauer A & Breitenecker G 1995 Prognostic value of tumour microvessel density in cancer of the uterine cervix stage IB to IIB. Anticancer Research 15 1549-1551.
65. Kerbel RS 1996 Commentaries on tumor angiogenesis: an introduction. Cancer Metastasis Review 15 145-147.
66. Kern FG & Lippman ME 1996 The role of angiogenic growth factors in breast cancer progression. Cancer Metastasis Review 15 213-219.
67. Kohno Y, Iwanari O & Kitao M 1993 Prognostic importance of histologic vascular density in cervical cancer treated with hypertensive intraarterial chemotherapy. Cancer 72 2394-2400.
68. Kurebayashi J, McLeskey SW, Johnson MD, Lippman ME, Dickson RB & Kern FG 1993 Quantitative demonstration of spontaneous metastasis by MCF-7 human breast cancer cells cotransfected with fibroblast growth factor 4 and LacZ. Cancer Research 53 2178-2187.
69. Lindman H, Taube A & Bergh JCS 1994 Suramin inhibits the growth of human breast cancer cell lines. Studies on parental lines and corresponding sublines with acquired doxorubicin resistance with and without expression of P-glycoprotein. Anticancer Research 14 363-366.
70. Macaulay VM, Fox SB, Zhang H, Whitehouse RM, Leek RD, Gatter KC, Bicknell R & Harris AL 1995 Breast cancer angiogenesis and tamoxifen resistance. Endocrine-Related Cancer 2 97-103.
71. McLaren J, Prentice A, Charnock-Jones DS, Millican SA, Müller KH, Sharkey AM & Smith SK 1996 Vascular endothelial growth factor is produced by peritoneal fluid macrophages in endometriosis and is regulated by ovarian steroids. Journal of Clinical Investigation 98 482-489.
72. McLeskey SW, Zhang L, Trock BJ, Kharbanda S, Liu Y, Gottardis MM, Lippman ME & Kern FG 1996 Effects of AGM-1470 and pentosan polysuphonate on tumorigenicity and metastasis of FGF-transfected MCFcells. British Journal of Cancer 73 1053-1062.
73. Maglione D, Guerriero V, Viglietto G, Ferraro MG, Aprelikova O, Alitalo K, Del Vecchio S, Lei K-J, Yang Chou J & Persico MG 1993 Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14. Oncogene 8 925-931.
74. Meyer GE, Yu E, Siegal JA, Petteway JC, Blumenstein BA & Brawer MK 1995 Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer 76 2304-2311.
75. Morgan KG, Wilkinson N & Buckley CH 1996 Angiogenesis in normal, hyperplastic, and neoplastic endometrium. Journal of Pathology 179 317-320.
76. Nakamoto T, Chang CS, Li AK & Chodak GW 1992 Basic fibroblast growth factor in human prostate cancer cells. Cancer Research 52 571-577.
77. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF & Folkman J 1994 Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. Journal of the National Cancer Institute 86 356-361.
78. Obermair A, Czerwenka K, Kurz C, Buxhaum P, Schemper M & Sevelda P 1994 Influence of tumoral microvessel density on the recurrence-free survival in human breast cancer: Preliminary results. Onkologie 17 44-49.
79. Obermair A, Kurz C, Czerwenka K, Tholma M, Kaider A, Wagner T, Gitsch G & Sevelda P 1995 Microvessel density and vessel invasion in lymph-node-negative breast cancer: effect on recurrence-free survival. International Journal of Cancer 62 126-131.
80. Ogawa Y, Chung Y-S, Nakata B, Takasuka S, Maeda K, Sawada T, Kato Y, Yoshikawa K, Sakurai M & Sowa M 1995 Microvessel quantitation in invasive breast cancer by staining for factor VIII-related antigen. British Journal of Cancer 71 1297-1301.
81. Olivarez D, Ulbright T, DeRiese W, Foster R, Reister T, Einhorn L & Sledge G 1994 Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Research 54 2800-2802.
82. Olson TA, Mohanraj D, Carson LF & Ramakrishnan S 1994 Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Research 54 276-280.
83. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH & Folkman J 1994 Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79 315-328.
84. O'Reilly MS, Holmgren L, Chen C & Folkman J 1996 Angiostatin induces and sustains dormancy of human primary tumors. Nature Medicine 2 689-692.
85. Osborne CK 1993 Regulation of breast cancer growth by steroid hormones and growth factors: Clinical implications. Cancer Bulletin 45 483-488.
86. Payson RA, Wu J, Liu Y & Chiu I-M 1996 The human FGF-8 gene localizes on chromosome 10q24 and is subjected to induction by androgen in breast cancer cells. Oncogene 13 47-53.
87. Penault-Llorca F, Bertucci F, Adelaide J, Pare P, Coulier F, Jacquemier J, Dirnbaum D & Delapeyriere O 1995 Expression of FGF and FGF receptor genes in human breast cancer. International Journal of Cancer 61 170-176.
88. Presta M 1988 Sex hormones modulate the synthesis of basic fibroblast growth factor in human endometrial adenocarcinoma cells: implications for the neovascularization of normal and neoplastic endometrium. Journal of Cellular Physiology 137 593-597.
89. Presta M, Maier JAM, Runati M, Moscatelli D & Ragnotti D 1988 Modulation of plasminogen activator activity in human endometrial adenocarcinoma cells, by basic fibroblast growth factor and transforming growth factor beta. Cancer Research 48 6384-6389.
90. Rak JW, St Croix BD & Kerbel RS 1995 Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anti-Cancer Drugs 6 3-18.
91. Reynolds K, Farzaneh F, Collins WP, Campbell S, Bourne TH, Lawton F, Moghaddam A, Harris AL & Bicknell R 1994 Association of ovarian malignancy with expression of platelet-derived endothelial growth factor. Journal of the National Cancer Institute 86 1234-1238.
92. Rutgers JL, Mattox TF & Vargas MP 1995 Angiogenesis in uterine cervical squamous cell carcinoma. International Journal of Gynecological Pathology 14 114-118.
93. Schlenger K, Hockel M, Mitze M, Schaffer U, Weikel W, Knapstein PG & Lambert A 1995 Tumor vascularity - a novel prognostic factor in advanced cervical carcinoma. Gynecological Oncology 59 57-66.
94. Seymour L & Bezwoda WR 1994 Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer. Breast Cancer Research and Treatment 32 229-233.
95. Shain SA, Saric T, Ke LD, Nannen D & Yoas S 1996 Endogenous fibroblast growth factor-1 or fibroblast growth factor-2 modulate prostate cancer cell proliferation. Cellular Growth and Differentiation 7 573-586.
96. Shing Y, Christofori G, Hanahan D, Ono Y, Sasada R, Igarashi K & Folkman J 1993 Betacellulin: a mitogen from pancreatic cell tumors. Science 259 1604-1607.
97. Siitonen SM, Haapasalo HK, Rantala IS, Helin HJ & Isola JJ 1995 Comparison of different immunohistochemical methods in the assessment of angiogenesis: Lack of prognostic value in a group of 77 selected node-negative breast carcinomas. Modern Pathology 8 745-752.
98. Silberman MA, Partin AW, Veltri RW & Epstein JI 1997 Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in Gleason sum 5 to 7 adenocarcinoma of the prostate. Cancer 79 772-779.
99. Sinowatz F, Amselgruber W, Lincoln D, Sasse J, Kolle S, Plendl J & Kayser K 1995 Role of basic fibroblast growth factor in prostate tumors. Nutrition 11 (Suppl 5) 619-621.
100. Smith-McCune KK & Weidner N 1994 Demonstration and characterization of the angiogenic properties of cervical dysplasia. Cancer Research 54 800-804.
101. Teicher BA, Sotomayor EA & Huang ZD 1992 Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Research 52 6702-6704.
102. Teicher BA, Holden SA, Ara G, Alvarez Sotomayor E, Huang ZD, Chen YN & Brem H 1994 Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. International Journal of Cancer 57 920-925.
103. Teicher BA, Holden SA, Dupuis NP, Kakeji Y, Ikebe M, Emi Y& Goff D 1995 Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Research and Treatment 36 227-236.
104. Terrier P, Townsend AJ, Coindre JM, Triche TJ & Cowan KH 1990 An immunohistochemical study of Pi class glutathione S-transferase expression in normal human tissues. American Journal of Pathology 137 845-853.
105. Toi M, Kashitani J & Tominaga T 1993a Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma. International Journal of Cancer 55 371-374.
106. Toi M, Yamamoto Y, Imazawa T, Takayanagi T, Azutsu K & Tominaga T 1993b Antitumor effect of the angiogenesis inhibitor AGM-1470 and its combination effect with tamoxifen in DMBA induced mammary tumors in rats. International Journal of Oncology 3 525-528.
107. Toi M, Hoshima S, Takayanagi T & Tominaga T 1994 Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Japanese Journal of Cancer Research 85 1045-1049.
108. Toi M, Inada K, Hoshina S, Suzuki H, Kondo S & Tominaga T 1995a Vascular endothelial growth factor and platelet-derived endothelial cell growth factor are frequently coexpressed in highly vascularized human breast cancer. Clinical Cancer Research 1 961-964.
109. Toi M, Hoshina S, Taniguchi T, Yamamoto Y, Ishitsuka H & Tominaga T 1995b Expression of platelet-derived endothelial cell growth factor/thymidine phosphorylase in human breast cancer. International Journal of Cancer 64 79-82.
110. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, Taniguchi T & Tominaga T 1996a Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 77 1101-1106.
111. Toi M, Taniguchi T, Yamamoto Y, Kurisaki T, Suzuki H & Tominaga T 1996b. Clinical significance of the determination of angiogenic factors. European Journal of Cancer 32A 2513-2519.
112. Trikha M, Timar J, Lundy SK, Szekeres K, Tang K, Grignon D, Porter AT & Honn KV 1996. Human prostate carcinoma cells express functional αIIbβ3 integrin. Cancer Research 56 5071-5078.
113. Tuszynski GP & Nicosia RF 1994 Localization of thrombospondin and its cysteine-serine valine-threonine-cystine-glycine specific receptor in human breast cancer. Laboratory Investigation 70 228-233.
114. Vesalainen S, Lipponen P, Talja M, Alhava E & Syrjanen K 1994 Tumor vascularity and basement membrane structure as prognostic factors in T1-2M0 prostatic adenocarcinoma. Anticancer Research 14 709-714.
115. Viglietto G, Maglione D, Rambaldi M, Cerutti J, Romano A, Trapasso F, Fedele M, Ippolito P, Chiappetta G, Botti G, Fusco A & Persico MG 1995 Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines. Oncogene 11 1569-1579.
116. Viglietto G, Romano A, Maglione R, Rambaldi M, Paoletti I, Iago CT, Califano D, Monaco C, Mineo A, Santelli G, Manzo G, Botti G, Chiappetta G & Persico MG 1996 Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene 13 577-587.
117. Volpert OV, Stellmach V & Bouck N 1995 The modulation of thrombospondin and other naturally occurring inhibitors of angiogenesis during tumor progression. Breast Cancer Research and Treatment 36 119-126.
118. Vrana JA, Stang MT, Grande JP & Getz MJ 1996 Expression of tissue factor in tumor stroma correlates with progression to invasive human breast cancer: Paracrine regulation by carcinoma cell-derived members of the transforming growth factor β family. Cancer Research 56 5063-5070.
119. Wakui S, Furusato M, Itoh T, Sasaki H, Akiyama A, Kinoshita I, Asano K, Tokuda T, Aizawa S & Ushigome S 1992 Tumour angiogenesis in prostatic carcinoma with and without bone marrow metastasis: a morphometric study. Journal of Pathology 168 257-262.
120. Weidner N 1996 Intratumoral vascularity as a prognostic factor in cancers of the urogenital tract. European Journal of Cancer 32A 2506-2512.
121. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred EN, Moore DH, Meli S & Gasparini G 1992 Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. Journal of the National Cancer Institute 84 1875-1887.
122. Weidner N, Carroll PR, Flax J, Blumenfeld W & Folkman J 1993 Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. American Journal of Pathology 168 257-262.
123. Weinstat-Saslow DL, Zabrenetzky VS, VanHoutte K, Frazier WA, Roberts DD & Steeg PS 1994 Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Research 54 6504-6511.
124. Wiggins DL, Granai CO, Steinhoff MM & Calabresi P 1995 Tumor angiogenesis as a prognostic factor in cervical carcinoma. Gynecological Oncology 56 353-356.
125. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T & Sadahito S 1994 Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Research 54 1630-1633.
126. Yao Y, Jin L, Fuchs A, Joseph A, Hastings HM, Goldberg ID & Rosen EM 1996 Scatter factor protein levels in human breast cancer. Clinicopathological and biological correlations. American Journal of Pathology 149 1707-1717.
127. Zajchowski DA, Band V, Trask DK, Kling D, Connolly JL & Sager R 1990 Suppression of tumor-forming ability and related traits in MCF-7 human breast cancer cell by fusion with immortal mammary epithelial cells. Proceedings of the National Academy of Sciences of the USA 87 2314-2318.
128. Zhang H-T, Craft P, Scott PAE, Ziehe M, Welch HA, Harris AL & Bicknell R 1995a Enhancement of tumor growth and vascular density by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. Journal of the National Cancer Institute 87 213-219.
129. Zhang L, Rees MCP & Bicknell R 1995b The isolation and long-term culture of normal human endometrial epithelium and stroma. Journal of Cellular Science 108 323-331.
130. Zuck B, Goepfert C, Nedlin-Chittka A, Sohrt K, Voigt KD & Knabbe C 1992 Regulation of fibroblast growth factor-like protein(s) in the androgen-responsive human prostate carcinoma cell line LNCAP. Journal of Steroid Biochemical Molecular Biology 41 3-8.